Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Marscha S Holleman, Harm van Tinteren, Harry JM Groen, Maiwenn J Al & Carin A Uyl-de Groot. (2019) First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis. OncoTargets and Therapy 12, pages 1413-1421.
Read now
Read now
Lina Zhang, Lei Shi, Xiaoting Zhao, Yue Wang & Wentao Yue. (2013) PIK3CA gene mutation associated with poor prognosis of lung adenocarcinoma. OncoTargets and Therapy 6, pages 497-502.
Read now
Read now
Roberto Ciarcia, Sara Damiano, Serena Montagnaro, Ugo Pagnini, Antonio Ruocco, Giuseppe Caparrotti, Danila d'Angelo, Silvia Boffo, Fátima Morales, Flavio Rizzolio, Salvatore Florio & Antonio Giordano. (2013) Combined effects of PI3K and SRC kinase inhibitors with imatinib on intracellular calcium levels, autophagy, and apoptosis in CML-PBL cells. Cell Cycle 12:17, pages 2839-2848.
Read now
Read now
Articles from other publishers (26)
Pooja Jaiswal, Versha Tripathi, Aakruti Nayak, Shreya Kataria, Vladimir Lukashevich, Apurba K. Das & Hamendra S. Parmar. (2021) A Molecular Link Between Diabetes and Breast Cancer: Therapeutic Potential of Repurposing Incretin-based Therapies for Breast Cancer. Current Cancer Drug Targets 21:10, pages 829-848.
Crossref
Crossref
Jinjin Duan, Li Wang, Liqun Shang, Shumei Yang, Hua Wu, Yongcheng Huang & Yi Miao. (2021) miR-152/TNS1 axis inhibits non-small cell lung cancer progression through Akt/mTOR/RhoA pathway. Bioscience Reports 41:1.
Crossref
Crossref
Xiao-yun Liu, Zi-tao Guo, Zhen-dong Chen, Yi-fan Zhang, Jia-lan Zhou, Yong Jiang, Qian-yu Zhao, Xing-xing Diao & Da-fang Zhong. (2020) Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer. Acta Pharmacologica Sinica 41:10, pages 1366-1376.
Crossref
Crossref
Jason C Hsu, Chen-Fang Wei, Szu-Chun Yang, Peng-Chan Lin, Yang-Cheng Lee & Christine Y Lu. (2020) Lung cancer survival and mortality in Taiwan following the initial launch of targeted therapies: an interrupted time series study. BMJ Open 10:5, pages e033427.
Crossref
Crossref
Hyunhee Do & Wanyeon Kim. (2018) Roles of Oncogenic Long Non-coding RNAs in Cancer Development. Genomics & Informatics 16:4, pages e18.
Crossref
Crossref
Cong Liu, Wei Hu, Lin-Lin Li, Yu-Xuan Wang, Qun Zhou, Feng Zhang, Yi-Yan Song-Yang, Wei Zhu, Cheng-Chao Sun & De-Jia Li. (2018) Roles of miR-200 family members in lung cancer: more than tumor suppressors. Future Oncology 14:27, pages 2875-2886.
Crossref
Crossref
Mahmoud Delphan, Tengda Lin, David B. Liesenfeld, Johanna Nattenmüller, Jürgen T. Böhm, Biljana Gigic, Nina Habermann, Lin Zielske, Petra Schrotz-King, Martin Schneider, Alexis Ulrich, Hans-Ulrich Kauczor, Cornelia M. Ulrich & Jennifer Ose. (2018) Associations of branched-chain amino acids with parameters of energy balance and survival in colorectal cancer patients: results from the ColoCare study. Metabolomics 14:3.
Crossref
Crossref
Charles J Malemud. (2015) The PI3K/Akt/PTEN/mTOR pathway: a fruitful target for inducing cell death in rheumatoid arthritis?. Future Medicinal Chemistry 7:9, pages 1137-1147.
Crossref
Crossref
Eva Regina Haspinger, Francesco Agustoni, Valter Torri, Francesco Gelsomino, Marco Platania, Nicoletta Zilembo, Rosaria Gallucci, Marina Chiara Garassino & Michela Cinquini. (2015) Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations. Critical Reviews in Oncology/Hematology 94:2, pages 213-227.
Crossref
Crossref
Xian-Guo Meng & Shou-Wei Yue. (2015) Dexamethasone Disrupts Cytoskeleton Organization and Migration of T47D Human Breast Cancer Cells by Modulating the AKT/mTOR/RhoA Pathway. Asian Pacific Journal of Cancer Prevention 15:23, pages 10245-10250.
Crossref
Crossref
Nahid Tamanna & Niaz Mahmood. (2014) Emerging Roles of Branched-Chain Amino Acid Supplementation in Human Diseases. International Scholarly Research Notices 2014, pages 1-8.
Crossref
Crossref
SOON-JAE KWON, JU-HYE LEE, KWANG-DEOG MOON, IL-YUN JEONG, SUNG-TAE YEE, MI-KYUNG LEE & KWON-IL SEO. (2014) Isoegomaketone induces apoptosis in SK-MEL-2 human melanoma cells through mitochondrial apoptotic pathway via activating the PI3K/Akt pathway. International Journal of Oncology 45:5, pages 1969-1976.
Crossref
Crossref
Paulina Olszewska, Jacek Szymański, Elżbieta Mikiciuk-Olasik & Paweł Szymański. (2014) New cyclopentaquinoline derivatives with fluorobenzoic acid induce G1 arrest and apoptosis in human lung adenocarcinoma cells. European Journal of Pharmacology 729, pages 30-36.
Crossref
Crossref
PENPAK MOOLTHIYA, RUTAIWAN TOHTONG, SIRIPORN KEERATICHAMROEN & KAWIN LEELAWAT. (2014) Role of mTOR inhibitor in cholangiocarcinoma cell progression. Oncology Letters 7:3, pages 854-860.
Crossref
Crossref
Hongwei Shao, Tao Peng, Zhiwei Ji, Jing Su & Xiaobo Zhou. (2013) Systematically Studying Kinase Inhibitor Induced Signaling Network Signatures by Integrating Both Therapeutic and Side Effects. PLoS ONE 8:12, pages e80832.
Crossref
Crossref
LI ZHANG, HAN-DONG WANG, XIANG-JUN JI, ZI-XIANG CONG, JIAN-HONG ZHU & YUAN ZHOU. (2013) FTY720 for cancer therapy (Review). Oncology Reports 30:6, pages 2571-2578.
Crossref
Crossref
Lohith Bachegowda, Oleg Gligich, Ionnis Mantzaris, Carolina Schinke, Dale Wyville, Tatiana Carrillo, Ira Braunschweig, Ulrich Steidl & Amit Verma. (2013) Signal transduction inhibitors in treatment of myelodysplastic syndromes. Journal of Hematology & Oncology 6:1.
Crossref
Crossref
Emin Avsar. 2013. Inhibitors of Molecular Chaperones as Therapeutic Agents. Inhibitors of Molecular Chaperones as Therapeutic Agents
336
378
.
HYUNSEUNG LEE, SOO JUNG KIM, KYUNG HEE JUNG, MI KWON SON, HONG HUA YAN, SUNGWOO HONG & SOON-SUN HONG. (2013) A novel imidazopyridine PI3K inhibitor with anticancer activity in non-small cell lung cancer cells. Oncology Reports 30:2, pages 863-869.
Crossref
Crossref
Yesol Bak, Sunyoung Ham, O. Baatartsogt, Seung hyun Jung, Kang-Duk Choi, Tae-Young Han, Il-Young Han & Do-Young Yoon. (2013) A1E inhibits proliferation and induces apoptosis in NCI-H460 lung cancer cells via extrinsic and intrinsic pathways. Molecular Biology Reports 40:7, pages 4507-4519.
Crossref
Crossref
Yang Yang, Yunxia Hu, Yuhua Wang, Jun Li, Feng Liu & Leaf Huang. (2012) Nanoparticle Delivery of Pooled siRNA for Effective Treatment of Non-Small Cell Lung Caner. Molecular Pharmaceutics 9:8, pages 2280-2289.
Crossref
Crossref
Zhe Chen, Xin Huang, Hongyu Yang, Wenbo Ding, Lingyan Gao, Ziqi Ye, Yandong Zhang, Yongping Yu & Yijia Lou. (2011) Anti-tumor effects of B-2, a novel 2,3-disubstituted 8-arylamino-3H-imidazo[4,5-g]quinazoline derivative, on the human lung adenocarcinoma A549 cell line in vitro and in vivo. Chemico-Biological Interactions 189:1-2, pages 90-99.
Crossref
Crossref
J.C. Soria, C. Massard & T. Le Chevalier. (2010) Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?. Annals of Oncology 21:12, pages 2324-2332.
Crossref
Crossref
Tetsuji Kurokawa, Guangan He & Zahid H. Siddik. (2009) Protein kinase inhibitors emodin and dichloro-ribofuranosylbenzimidazole modulate the cellular accumulation and cytotoxicity of cisplatin in a schedule-dependent manner. Cancer Chemotherapy and Pharmacology 65:3, pages 427-436.
Crossref
Crossref
J.-C. Soria, F.A. Shepherd, J.-Y. Douillard, J. Wolf, G. Giaccone, L. Crino, F. Cappuzzo, S. Sharma, S.H. Gross, S. Dimitrijevic, L. Di Scala, H. Gardner, L. Nogova & V. Papadimitrakopoulou. (2009) Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Annals of Oncology 20:10, pages 1674-1681.
Crossref
Crossref
Timothy Craig Allen. (2008) Pulmonary Neoplasia. Archives of Pathology & Laboratory Medicine 132:7, pages 1053-1054.
Crossref
Crossref